Roel Meers

Roel advises clients in the field of corporate finance, covering mergers and acquisitions (public and private), private equity transactions, as well as security offerings, listings and other capital market transactions. He also advises on complex corporate restructurings, corporate governance matters, and shareholder activism.

The corporate finance and capital markets expertise of Baker McKenzie in Belgium is consistently recognised by Chambers, Legal 500 and IFLR 1000 as one of the main corporate finance teams in Belgium advising on a wide range of complex, often cross-border M&A, private equity, and public market transactions, including public M&A and takeover attempts, buyouts, and spin-offs.

Capital markets transactions

• Advised Galapagos, a biotech company listed on Euronext Brussels, Euronext Amsterdam and NASDAQ, on its transformative USD 5.1 billion research and development collaboration with Gilead Sciences in 2019.
• Advised MDxHealth, a commercial-stage precision diagnostics company, on its EUR 45 million initial public offering and listing on NASDAQ, as well as several security offerings and listings on NASDAQ and Euronext Brussels.
• Advised Mithra Pharmaceuticals, a company specialised in women's health (listed on Euronext Brussels), on its licence and supply agreement with Mayne Pharma Group Limited for an exclusive licence to commercialise Estelle® in the US, and several of its accelerated bookbuild private placements of new shares with listing on Euronext Brussels and its EUR 150 million debut offering of convertible bonds.
• Advised the underwriters of Umicore, a materials technology company (listed on Euronext Brussels), on the company's debut offering of EUR 500 million senior unsecured zero coupon convertible bonds due 2025.
• Advised the underwriters of Nyxoah, a medical device company, on the company's EUR 85 million initial public offering with listing on Euronext Brussels.
• Advised the underwriters of Biotalys, an agricultural technology (AgTech) company, on the company's EUR 53 million initial public offering with listing on Euronext Brussels.
• Advised the underwriters of TINC, an infrastructure company, on the company's EUR 110 million initial public offering in 2015 with listing on Euronext Brussels, and its subsequent rights offerings.
• Advised Sequana Medical, a commercial-stage medical device company, on its EUR 27.5 million initial public offering in 2019 with listing on Euronext Brussels, and its subsequent accelerated bookbuild private placements.
• Advised the underwriters of Materialise, a 3D printing specialist, on the company's USD 110 million initial public offering with listing on NASDAQ.

M&A transactions

• Advised Galapagos, a biotech company listed on Euronext Brussels, Euronext Amsterdam and NASDAQ, on its acquisition of CellPoint, a privately held biotech company dedicated to developing CAR-T therapies at the point-of-care, for an upfront amount of EUR 125 million, with milestone payments up to EUR 100 million.
• Advised Panasonic on the EUR 294 million acquisition of Zetes Industries (listed on Euronext Brussels), via the acquisition of a controlling stake followed by a mandatory public tender offer and squeeze-out offer for Zetes Industries' remaining securities.
• Advised Agfa (listed on Euronext Brussels) on the strategic alliance of Agfa Graphics with Lucky HuaGang Graphics, a Chinese state-owned enterprise (SOE).
• Advised KBC (listed on Euronext Brussels) on the EUR 1.5 billion sale of Antwerp Diamond Bank.

• Brussels Bar (Dutch language section) - Member